**Instructions for Canada PCT National Phase Entry**

**I. Client Information**

|  |  |
| --- | --- |
| Name: |  |
| Address: |  |
| Tel.: |  |
| Fax: |  |
| E-mail: |  |
| Ref. No.: |  |

**II. Application Particulars**

|  |  |
| --- | --- |
| **International Application No.** | **International Filing Date** |
|  |  |

|  |  |
| --- | --- |
| Title of Invention: |  |

Canadian National Phase Entry required under:

 [ ] PCT Chapter I [ ] PCT Chapter II

Convention priority claim(s) is based on:

|  |  |  |
| --- | --- | --- |
| **Country** | **Application Serial Number** | **Filing Date** (dd/mm/yy) |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |

 [ ] additional Convention priority claim(s) is attached

**III. Inventor Information**

[ ]  Please use the inventor information currently on file with WIPO

[ ]  Inventor information is supplied below if:

1. PCT application is not yet published
2. The information currently on file is not up to date

*Inventor #1 (if applicable):*

|  |  |
| --- | --- |
| Name: |  |
| Address: |  |

*Inventor #2 (if applicable):*

|  |  |
| --- | --- |
| Name: |  |
| Address: |  |

*Inventor #3(if applicable):*

|  |  |
| --- | --- |
| Name: |  |
| Address: |  |

*Inventor #4 (if applicable):*

|  |  |
| --- | --- |
| Name: |  |
| Address: |  |

*Inventor #5 (if applicable):*

|  |  |
| --- | --- |
| Name: |  |
| Address: |  |

 [ ] information on additional inventor(s) is attached

**IV. Applicant Information**

[ ]  Please use the Applicant information currently on file with WIPO

[ ]  Applicant information is supplied below if:

1. PCT application is not yet published
2. The information currently on file with WIPO is not up to date

[ ]  Applicant(s) is the inventor(s)

*Applicant #1 (if applicable):*

|  |  |
| --- | --- |
| Name: |  |
| Address: |  |

*Applicant #2 (if applicable):*

|  |  |
| --- | --- |
| Name: |  |
| Address: |  |

 [ ] information on additional applicant(s) is attached

**V. Request for Examination1**

[ ] Request examination at time of filing [ ] Defer request for examination

1Canada uses a deferred examination system. The applicant must file a request for examination and pay the government examination fee within 4 years of the international filing date of the PCT application (5 years for international applications filed prior to October 30, 2019). Please indicate whether we should request examination when we file the application, or defer such request for the time being.

**VI. Entity Size2**

[ ]  Applicant(s) does not claim small entity status

[ ]  Applicant(s) claims small entity status and acknowledges and accepts the risks of incorrectly claiming small entity status. Please forward a small entity declaration for signature by the Applicant(s).

2A “small entity” for fee purposes is an entity that employs 50 or fewer employees or that is a university. Small entity status does not apply to an entity that (a) is controlled directly or indirectly by an entity, other than a university, that employs more than 50 employees; or (b) has transferred or licensed or has an obligation, other than a contingent obligation, to transfer or license any right in the invention to an entity, other than a university, that employs more than 50 employees.

**A Canadian patent can potentially be invalidated if any fee is improperly paid on the small entity scale.** If there is any doubt as to entity status, we recommend against claiming small entity status.

**VII. Accompanying Documents**

|  |  |
| --- | --- |
| PCT Request | Enclosed [ ]  To Follow [ ]  Obtain from WIPO [ ]  |
| IB/306 Recording of Change | Enclosed [ ]  To Follow [ ]  Obtain from WIPO [ ]  |
| International Application as originally filed (Word format) | Enclosed [ ]  To Follow [ ]  |
| International Application as published | Enclosed [ ]  To Follow [ ]  Obtain from WIPO [ ]  |
| English or French translation of International Application (due at the time of national phase entry) | Enclosed [ ]  To Follow [ ] N/A (Application published in English or French) [ ]  |
| International Search Report | Enclosed [ ]  To Follow [ ]  Obtain from WIPO [ ]  |
| Article 19 Amendments (if any) | Enclosed [ ]  To Follow [ ]  Obtain from WIPO [ ]  |
| International Preliminary Examination Report (Chapter II only) | Enclosed [ ]  To Follow [ ]  N/A [ ]  |
| Article 34 Amendments (if any) | Enclosed [ ]  To Follow [ ]  N/A [ ]  |
| Transfer(s) (if any)3 | Enclosed [ ]  To Follow [ ]  N/A [ ]  |
| Sequence Listing (if any)4 | Enclosed [ ]  To Follow [ ]  N/A [ ]  |
| Certified Copy or WIPO DAS code for each Priority Application5 | Enclosed [ ]  To Follow [ ]  N/A [ ] Previously provided to WIPO [ ]  |

3The CIPO no longer requires an applicant to record transfers or other title documents to substantiate the applicant’s entitlement to apply for a patent. Even though the CIPO will not require us to do so, we recommend that you provide and instruct us to file copies of any relevant transfers or other title documents which establish the chain of title from the inventor(s) to the applicant. We also recommend that any future changes in ownership of the patent rights (e.g. assignments, mergers, name changes, etc.) be recorded in the CIPO.

4An application which discloses nucleotide or amino acid sequences that do not form part of the prior art must contain a sequence listing in computer-readable form containing the actual sequence(s).

5A certified copy of each application from which priority is claimed must be filed at the time of national phase entry unless this was provided to WIPO during the international phase. A Digital Access Service code from WIPO may be provided instead.

**VIII. Documents Not Required for Canada**

We can request National Entry **without** a signed Power of Attorney.

**IX. Special Instructions**

|  |  |
| --- | --- |
| Filing deadline: |  |
| Additional instructions: |  |

 [ ] further additional instructions are attached

**X. Mailing Instructions**

Please send completed form and attachments to Oyen Wiggs Green & Mutala LLP via:

* E-mail to mail@patentable.com, or
* Fax to 604.681.4081, or
* Courier to address below.